Entera Bio (ENTX) vs Prothena (PRTA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Entera Bio (ENTX) has outperformed Prothena (PRTA) over the past year, gaining 32.8% versus a loss of 16.6%. Over five years, ENTX leads with a -44.5% price change compared with -86.6% for PRTA. Entera Bio is the larger company by market cap ($436.3 million vs $435.3 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ENTX | PRTA |
|---|---|---|
| Share price | $2.51 | $8.48 |
| Market cap | $436.32M | $435.34M |
| 1-day change | -0.79% | +5.74% |
| YTD return | +29.38% | -11.20% |
| 1-year return | +32.80% | -16.62% |
| 5-year return | -44.47% | -86.64% |
| EPS (TTM) | $-0.36 | $-0.87 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $4.20 | $11.80 |
| 52-week low | $0.91 | $7.73 |
| Distance from 52-week high | -40.24% | -28.14% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +288.45% | +152.36% |
| Average volume | 1.81M | 478.70K |
| Shares outstanding | 173.83M | 51.34M |
| Employees | 20 | 67 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ENTX has outperformed PRTA by 49.4 percentage points over the past year.
About Entera Bio
ENTX stock →Entera Bio Ltd., a clinical stage company, engages in the development of oral peptides and protein replacement therapies in Israel and internationally. It develops EB613, an oral teriparatide, which completed the Phase II clinical trial for the treatment of osteoporosis and Phase I clinical trial for the treatment of stress fractures.
Healthcare · Biotechnology · 20 employees
About Prothena
PRTA stock →Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation. Its product pipeline includes Prasinezumab, an investigational humanized monoclonal antibody which is in Phase 3 clinical trial for the treatment of parkinson's disease and other synucleinopathies.
Healthcare · Biotechnology · 67 employees
ENTX vs PRTA FAQ
Which is bigger, Entera Bio or Prothena?
Entera Bio (ENTX) is larger, with a market capitalization of $436.32M compared with $435.34M for Prothena (PRTA).
Which stock has performed better over the past year, ENTX or PRTA?
ENTX returned +32.80% over the past 12 months, compared with -16.62% for PRTA (price return, excluding dividends). Past performance does not predict future results.
Are Entera Bio and Prothena in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.